Camptothecins and lung cancer: Improved delivery systems by aerosol

Current Cancer Drug Targets

Volumn 3, Issue 4, 2003, Pages 251-264

  Koshkina, N V ^a,b   Waldrep, J C ^a   Knight, V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 SILYLCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTIMETABOLITE; ANTIMITOTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYCLOPHOSPHAMIDE; DB 67; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ENDONUCLEASE; ETOPOSIDE; EXATECAN; FLUOROURIDINE; GEMCITABINE; IRINOTECAN; KARENITECIN; LIPOSOME; LURTOTECAN; MICROSPHERE; NANOCAPSULE; PACLITAXEL; POLYMER; RUBITECAN; SERINE PROTEINASE; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

AEROSOL; DNA REPLICATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; LUNG CANCER; LUNG METASTASIS; MELANOMA; NONHUMAN; OSTEOSARCOMA; PHARMACEUTICAL ENGINEERING; REVIEW; RNA REPLICATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CAMPTOTHECIN; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0042630937     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481930     Document Type: Review

References (112)

1. Wall, M. E.; Wani, M. C. Camptothecin. Discovery to Clinic. Ann. N. Y. Acad. Sci. 1996, 803, 1-12.
2. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M.; Pommier, Y. Structure-Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for A Specific Receptor Site and a Relation to Antitumor Activity. Cancer Res. 1989, 49, 1465-1469.
3. Pommier, Y.; Gupta, M.; Valenti, M.; Nieves-Neira, W. Cellular Resistance to Camptothecins. Ann. N. Y. Acad. Sci. 1996, 803, 60-73.
4. Husain, I.; Mohler, J. L.; Seigler, H. F.; Besterman, J.M. Elevation of Topoisomerase I Messenger RNA, Protein, and Catalytic Activity in Human Tumors: Demonstration of Tumor-Type Specificity and Implications for Cancer Chemotherapy. Cancer Res. 1994, 54, 539-546.
5. Guichard, S.; Terret, C.; Hennebelle, I.; Lochon, I.; Chevreau, P.; Fretigny, E.; Selves, J.; Chatelut, E.; Bugat, R.; Canal, P. CPT-11 Converting Carboxylesterase and Topoisomerase Activities in Tumour and Normal Colon and Liver Tissues. Br. J. Cancer 1999, 80, 364-370.
6. Goldwasser, F.; Shimizu, T.; Jackman, J.; Hoki, Y.; O'Connor, P.M.; Kohn, K.W.; Pommier, Y. Correlations Between S and G2 Arrest and the Cytotoxicity of Camptothecin in Human Colon Carcinoma Cells. Cancer Res. 1996, 56, 4430-4437.
7. Morris, E. J.; Geller, H. M. Induction of Neuronal Apoptosis By Camptothecin, An Inhibitor of DNA Topoisomerase-I: Evidence for Cell Cycle-Independent Toxicity. J. Cell Biol. 1996, 134, 757-770.
8. Clements, M. K.; Jones, C. B.; Cumming, M.; Daoud, S. S. Antiangiogenic Potential of Camptothecin and Topotecan. Cancer Chemother. Pharmacol. 1999, 44, 411-416.
9. O'Leary, J. J.; Shapiro, R. L.; Ren, C. J.; Chuang, N.; Cohen, H. W.; Potmesil, M. Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20(S)-Camptothecin, Topotecan, and CPT-11 Studied in the Mouse Cornea Model. Clin. Cancer Res. 1999, 5, 181-187
10. Wall, M, E.; Wani, M.C.; Taylor H. Isolation and Chemical Characterization of Antitumor Agents From Plants. Cancer Treat. Rep. 1976, 60, 1011-1030
11. th Int Symp Biochem Physiol Alkaloide; Mothes, K.; Schrieber, K.; Schutte, H. K., Eds., Berlin: Acad Verlag, 1969, Pp. 77-87
12. Wani, M. C.; Ronman, P. E.; Lindley, J.T.; Wall, M.E. Plant Antitumor Agents. 18. Synthesis and Biological Activity of Camptothecin Analogues. J. Med. Chem. 1980, 23, 554-560
13. Giovanella, B. C.; Stehlin, J. S.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Liu, L. F.; Silber, R.; Potmesil, M. DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts. Science 1989, 246, 1046-1048
14. Stehlin, J. S.; Giovanella, B. C.; Natelson, E. A.; De Ipolyi, P. D.; Coil, D.; Davis, B.; Wolk, D.; Wallace, P.; Trojacek, A. A Study of 9-Nitrocamptothecin (RFS-2000) in Patients with Advanced Pancreatic Cancer. Int. J. Oncol. 1999, 14, 821-831.
15. Mi, Z.; Burke T. G. Differential Interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components. Biochemistry 1994, 33, 10325-10336.
16. Mi, Z.; Burke T. G. Marked Interspecies Variations Concerning the Interactions of Camptothecin with Serum Albumins: A Frequency-Domain Fluorescence Spectroscopic Study. Biochemistry 1994, 33, 12540-12545.
17. Arbuck, S. G.; Takimoto, C. H. An Overview of Topoisomerase I-Targeting Agents. Semin. Hemato 1. 1998, 35 (Suppl. 4), 3-12.
18. Saijo, N. Preclinical and Clinical Trials of Topoisomerase Inhibitors. Ann. N. Y. Acad. Sci. 2000, 922, 92-99.
19. Sharma, S.; Kemeny, N.; Schwartz, G. K.; Kelsen, D.; O'Reilly, E.; Ilson, D.; Coyle, J.; De Jager, R. L.; Ducharme, M. P.; Kleban, S.; Hollywood, E.; Saltz, L. B. Phase I Study of Topoisomerase I Inhibitor Exatecan Mesylate (DX-8951f) Given As Weekly 24-Hour Infusions Three of Every Four Weeks. Clin. Cancer Res. 2001, 7, 3963-3970.
20. Stevenson, J. P.; Demaria, D.; Sludden, J.; Kaye, S. B.; Paz-Ares, L.; Grochow, L. B.; Mcdonald, A.; Selinger, K.; Wissel, P.; O'Dwyer, P. J.; Twelves, C. Phase I/Pharmacokinetic Study of the Topoisomerase I Nhibitor GG211 Administered As A 21-Day Continuous Infusion. Ann. Oncol. 1999, 10, 339-344.
21. Verschraegen, C. F.; Gupta, E.; Loyer, E.; Kavanagh, J. J.; Kudelka, A. P.; Freedman, R. S.; Edwards, C.; Harris, N.; Steger, M.; Steltz, V.; Giovanella, B. C.; Stehlin, J. S. A Phase II Clinical and Pharmacological Study of Oral 9-Nitrocamptothecin in Patients with Refractory Epithelial Ovarian, Tubal Or Peritoneal Cancer. Anticancer Drugs 1999, 10, 375-383.
22. Burke, T. G.; Munshi, C. B.; Mi, Z.; Jiang, Y. The Important Role of Albumin in Determining The Relative Human Blood Stabilities of The Camptothecin Anticancer Drugs. J. Pharm. Sci. 1995, 84, 518-519.
23. Loos, W.; Verweij, J.; Gelderblom, H. J.; De Jonge, M. J.; Brouwer, E.; Dallaire, B. K.; Sparreboom, A. Role of Erythrocytes and Serum Proteins in The Kinetic Profile of Total 9-Amino-20(S)-Camptothecin in Humans. Anticancer Drugs 1999, 10, 705-710.
24. Hochberg, F.; Grossman, S. A.; Mikkelsen, T.; Glantz, M.; Fisher, J. D.; Piantadosi, S. Lack of Efficacy of 9-Aminocamptothecin in Adults with Newly Diagnosed Glioblastoma Multiforme and Recurrent High-Grade Astrocytoma. NABTT CNS Consortium. Neuro-Oncol. 2000, 2, 29-33.
25. Takimoto, C. H.; Dahut, W.; Harold, N.; Nakashima, H.; Lieberman, R.; Liang, M. D.; Arbuck, S.; Chen, A. P.; Hamilton, J. M.; Cantilena, L. R.; Allegra, C. J.; Grem, J. L. Clinical Pharmacology of 9-Aminocamptothecin. Ann. N. Y. Acad. Sci. 1996, 803, 324-326.
26. Saltz, L. B.; Kemeny, N. E.; Tong, W.; Harrison, J.; Berkery, R.; Kelsen, D. P. 9-Aminocamptothecin by 72-Hour Continuous Intravenous Infusion is Inactive in the Treatment of Patients with 5-Fluorouracil-Refractory Colorectal Carcinoma. Cancer 1997, 80, 1727-1732.
27. Lesueur-Ginot, L.; Demarquay, D.; Kiss, R.; Kasprzyk, P. G.; Dassonneville, L.; Bailly, C.; Camara, J.; Lavergne, O.; Bigg, D. C. Homocamptothecin. An E-Ring Modified Camptothecin with Enhanced Lactone Stability, Retains Topoisomerase I-Targeted Activity and Antitumor Properties. Cancer Res. 1999, 59, 2939-2943.
28. Lavergne, O.; Demarquay, D.; Kasprzyk, P. G.; Bigg, D.C. Homocamptothecins: E-Ring Modified CPT Analogues. Ann. N. Y. Acad. Sci. 2000, 922, 100-111.
29. Bailly, C.; Lansiaux, A.; Dassonneville, L.; Demarquay, D.; Coulomb, H.; Huchet, M.; Lavergne, O.; Bigg, D. C. Homocamptothecin, An E-Ring-Modified Camptothecin Analogue, Generates New Topoisomerase I-Mediated DNA Breaks. Biochemistry 1999, 38, 15556-15563.
30. Demarquay, D.; Huchet, M.; Coulomb, H.; Lesueur-Ginot, L.; Lavergne, O.; Kasprzyk, P. G.; Bailly, C.; Camara, J.; Bigg, D. C. The Homocamptothecin BN80915 is a Highly Potent Orally Active Topoisomerase I Poison. Anticancer Drugs 2001, 12, 9-19.
31. Bom, D.; Curran, D. P.; Kruszewski, S.; Zimmer, S. G.; Thompson Srode, J.; Kohlhagen, G.; Du, W.; Chavan, A. J.; Fraley. K.A.; Bingcang, A. L.; Latus, L. J.; Pommier, Y.; Burke, T. G. The Novel Silatecan 7-Tert-Butyldimethylsilyl-10-Hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity. J. Med. Chem. 2000, 43, 3970-3980.
32. Keir, S. T.; Hausheer, F.; Lawless, A. A.; Bigner, D.; Friedman, H. S. Therapeutic Activity of 7-[(2-Trimethylsilyl)Ethyl)]-20 (S)-Camptothecin Against Central Nervous System Tumor-Derived Xenografts in Athymic Mice. Cancer Chemother. Pharmacol. 2001, 48, 83-87.
33. Toloza, E. M.; Roth, J. A.; Swisher, S. G. Molecular Events in Bronchogenic Carcinoma and Their Implications for Therapy. Semin. Surg. Oncol. 2000, 18, 91-99.
34. Negoro, S.; Fukuoka, M.; Niitani, H.; Suzuki, A.; Nakabayashi, T.; Kimura, M.; Motomiya, M.; Kurita, Y.; Hasegawa, K.; Kuriyama, T. A Phase II Study of CPT-11, A Camptothecin Derivative, in Patients with Primary Lung Cancer. CPT-11 Cooperative Study Group. Gan to Kagaku Ryoho, 1991, 18, 1013-1019.
35. Fukuoka, M.; Niitani, H.; Suzuki, A.; Motomiya, M.; Hasegawa, K.; Nishiwaki, Y.; Kuriyama, T.; Ariyoshi, Y.; Negoro, S.; Masuda, N.A. Phase II Study of CPT-11, A New Derivative of Camptothecin, for Previously Untreated Non-Small-Cell Lung Cancer. J. Clin. Oncol. 1992, 10, 16-20.
36. Masuda, N.; Fukuoka, M.; Kusunoki, Y.; Matsui, K.; Takifuji, N.; Kudoh, S.; Negoro, S.; Nishioka, M.; Nakagawa, K.; Takada M. CPT-11: A New Derivative of Camptothecin for The Treatment of Refractory Or Relapsed Small-Cell Lung Cancer. J. Clin. Oncol. 1992, 10, 1225-1229.
37. Lynch, T. J. Jr.; Kalish, L.; Strauss, G.; Elias, A.; Skarin, A.; Shulman, L. N.; Posner, M.; Frei, E. 3rd. Phase II Study of Topotecan in Metastatic Non-Small-Cell Lung Cancer. J. Clin. Oncol. 1994, 12, 347-352.
38. Perez-Soler, R.; Fossella, F. V.; Glisson, B. S.; Lee, J. S.; Murphy, W. K.; Shin, D. M.; Kemp, B. L.; Lee, J. J.; Kane, J.; Robinson, R. A.; Lippman, S.M.; Kurie, J. M.; Huber, M. H.; Raber, M. N.; Hong, W. K. Phase II Study of Topotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Untreated with Chemotherapy. J. Clin. Oncol. 1996, 14, 503-513.
39. Schiller, J. H.; Kim, K.; Hutson, P.; Devote, R.; Glick, J.; Stewart, J.; Johnson, D. Phase II Study of Topotecan in Patients with Extensive-Stage Small-Cell Carcinoma of the Lung: An Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 1996, 14, 2345-2352.
40. Perez-Soler, R.; Glisson, B. S.; Lee, J. S.; Fossella, F. V.; Murphy, W. K.; Shin, D. M.; Hong, W. K. Treatment of Patients with Small-Cell Lung Cancer Refractory to Etoposide and Cisplatin with The Topoisomerase I Poison Topotecan. J. Clin. Oncol. 1996, 14, 2785-2790.
41. Lima, C.M.; Chiappori, A. Treatment of Relapsed Small-cell Lung Cancer - A Focus on the Evolving Role of Topotecan. Lung Cancer 2003, 40, 229-236.
42. Feng, F.; He, X.; Shi, Y. Clinical Study of Topotecan in the Treatment of Small Cell Lung Cancer and Recurrent Ovarian Cancer. Zhonghua Zhong Liu Za. Zhi. 2001, 23, 155-158.
43. Ardizzoni, A.; Hansen, H.; Dombernowsky, P.; Gamucci, T.; Kaplan, S.; Postmus, P.; Giaccone, G.; Schaefer, B.; Wanders, J.; Verweij, J. Topotecan, A New Active Drug in The Second-Line Treatment of Small-Cell Lung Cancer: A Phase II Study in Patients with Refractory and Sensitive Disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development of fice, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 1997, 15, 2090-2096.
44. Wall, J. G.; Burris, H. A. 3rd.; Von Hoff D. D.; Rodriguez, G.; Kneuper-Hall, R.; Shaffer, D.; O'Rourke, T.; Brown, T.; Weiss, G.; Clark, G.A. Phase I Clinical and Pharmacokinetic Study of the Topoisomerase I Inhibitor Topotecan (SK&F 104864) Given As An Intravenous Bolus Every 21 Days. Anticancer Drugs 1992, 3, 337-345.
45. Eckhardt, S.G.; Baker, S.D.; Eckardt, J.R.; Burke, T.G.; Warner, D.L.; Kuhn, J.G.; Rodriguez, G.; Fields, S.; Thurman, A.; Smith, L.; Rothenberg, M.L.; White, L.; Wissel, P.; Kunka, R.; Depee, S.; Littlefield, D.; Burris, H.A.; Von Hoff, D.D.; Rowinsky, E.K. Phase I and Pharmacokinetic Study of GI147211, A Water-Soluble Camptothecin Analogue, Administered for Five Consecutive Days Every Three Weeks. Clin. Cancer Res. 1998, 4, 595-604.
46. Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H.; Pavlidis, N.; Verweij, J.; Sessa, C.; Kaye, S.; Roelvink, M.; Wanders, J.; Hanauske, A. Activity and Toxicity of GI147211 in Breast, Colorectal and Non-Small-Cell Lung Cancer Patients: an EORTC-ECSG Phase II Clinical Study. Ann. Oncol. 2000, 11, 793-797.
47. Joto, N.; Ishii, M.; Minami, M.; Kuga, H.; Mitsui, I.; Tohgo, A. DX-8951f, A Water-Soluble Camptothecin Analog, Exhibits Potent Antitumor Activity Against a Human Lung Cancer Cell Line and Its SN-38-Resistant Variant. Int. J. Cancer 1997, 72, 680-686.
48. Kumazawa, E.; Jimbo, T.; Ochi, Y.; Tohgo, A. Potent and Broad Antitumor Effects of DX-8951f, a Water-Soluble Camptothecin Derivative, Against Various Human Tumors Xenografted in Nude Mice. Cancer Chemother. Pharmacol. 1998, 42, 210-220.
49. Ishii, M.; Iwahana, M. Mitsui, I.; Minami, M.; Imagawa, S.; Tohgo, A.; Ejima, A. Growth Inhibitory Effect of a New Camptothecin Analog, DX-8951f, on Various Drug-Resistant Sublines Including BCRP-Mediated Camptothecin Derivative-Resistant Variants Derived From The Human Lung Cancer Cell Line PC-6. Anticancer Drugs 2000, 11, 353-362.
50. Negoro, S.; Fukuoka, M.; Masuda, N.; Takada, M.; Kusunoki, Y.; Matsui, K.; Takifuji, N.; Kudoh, S.; Niitani, H.; Taguchi, T. Phase I Study of Weekly Intravenous Infusions of CPT-11, A New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer. J. Natl. Cancer Inst. 1991, 83, 1164-1168.
51. Rowinsky, E. K.; Grochow, L. B.; Ettinger, D. S.; Sartorius, S. E.; Lubejko, B. G.; Chen, T. L.; Rock, M. K.; Donehower, R. C. Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-Piperidino)-1-Piperidino]Carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks. Cancer Res. 1994, 54, 427-436.
52. Pantazis, P.; Kozielski, A. J.; Vardeman, D. M.; Petry, E.R.; Giovanella, B. C. Efficacy of Camptothecin Congeners in The Treatment of Human Breast Carcinoma Xenografts. Oncol. Res., 1993, 5, 273-281.
53. Pantazis, P.; Kozielski, A.; Rodriguez, R.; Petry, E.; Wani, M.; Wall, M.; Giovanella. B. Therapeutic Efficacy of Camptothecin Derivatives Against Human Malignant Melanoma Xenografts. Melanoma Res. 1994, 4, 5-10.
54. Knight, V.; Koshkina, N. V.; Waldrep, J. C.; Giovanella, B. C.; Gilbert, B. E. Anticancer Effect of 9-Nitrocamptothecin Liposome Aerosol on Human Cancer Xenografts in Nude Mice. Cancer Chemother. Pharmacol. 1999, 44, 177-186.
55. Sparreboom, A.; De Jonge, M. J.; Punt, C. J.; Nooter, K.; Loos, W. J.; Porro, M. G.; Verweij J. Pharmacokinetics and Bioavailability of Oral 9-Aminocamptothecin Capsules in Adult Patients with Solid Tumors. Clin. Cancer Res. 1998, 4, 1915-1919.
56. Mani, S.; Iyer, L.; Janisch, L.; Wang, X.; Fleming, G.F.; Schilsky, R.L.; Ratain, M.J. Phase I Clinical and Pharmacokinetic Study of Oral 9-Aminocamptothecin (NSC-603071). Cancer Chemother. Pharmacol. 1998, 42, 84-87.
57. Rubin, E.; Wood, V.; Bharti, A.; Trites, D.; Lynch, C.; Hurwitz, S.; Bartel, S.; Levy, S.; Rosowsky, A.; Toppmeyer, D. A Phase I and Pharmacokinetic Study of a New Camptothecin Derivative, 9-Aminocamptothecin. Clin. Cancer Res. 1995, 1, 269-276.
58. Vey, N.; Kantarjian, H.; Tran, H.; Beran, M.; O'Brien, S.; Bivins, C.; Giles, F.; Cortes, J.; Cheson, B.; Arbuck, S.; Estey, E. Phase I and Pharmacologic Study of 9-Aminocamptothecin Colloidal Dispersion Formulation in Patients with Refractory Or Relapsed Acute Leukemia. Ann. Oncol. 1999, 10, 577-583.
59. Muggia, F.; Liebes, L.; Potmesil, M.; Hamilton, A.; Hochster, H.; Hornreich, G.; Sorich, J.; Downey, A.; Wasserstrom, H. Intraperitoneal Topoisomerase-I Inhibitors. Preliminary Findings with 9-Aminocamptothecin. Ann. N. Y. Acad. Sci. 2000, 922, 178-187.
60. Vokes, E. E.; Ansari, R. H.; Masters, G. A.; Hoffman, P. C.; Klepsch, A.; Ratain, M. J.; Sciortino, D. F.; Lad, T. E.; Krauss, S.; Fishkin, P. A.; Golomb, H. M. A Phase II Study of 9-Aminocamptothecin in Advanced Non-Small-Cell Lung Cancer. Ann. Oncol. 1998, 9, 1085-1090.
61. Vokes, E. E.; Gordon, G.; Rudin, C. M.; Mauer, A. M.; Watson, S.; Krauss, S.; Arrieta, R.; Golomb, H. M.; Hoffman, P. C. A Phase II Trial of 9-Aminocaptothecin (9-AC) As A 120-H Infusion in Patients with Non-Small Cell Lung Cancer. Invest. New Drugs 2001, 19, 329-333.
62. Perez-Soler, R.; Lopez-Berestein, G.; Kasi, L.P.; Cabanillas, F.; Jahns, M.; Glenn, H.; Hersh, E.M.; Haynie, T. Distribution of Technetium-99m-Labeled Multilamellar Liposomes in Patients with Hodgkin's Disease. J. Nucl. Med. 1985, 26, 743-749.
63. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz Y. Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-Glycol Coated Liposomes. Cancer Res. 1994, 54, 987-992.
64. Lasic, D.D. Doxorubicin in Sterically Stabilized Liposomes. Nature 1996, 380, 561-562
65. Papahadjopoulos, D.; Allen, T. M.; Gabizon, A.; Mayhew B.; Matthay, K.; Huang, S. K.; Lee, K. D.; Woodle, M. C.; Lasic, D. D.; Redemann, C.; Martin, F. J. Sterically Stabilized Liposomes: Improvements in Pharmacokinetics and Antitumor Therapeutic Efficacy. Proc. Natl. Acad. Sci. USA 1991, 88, 11460-11464.
66. Wu, N. Z.; Da, D.; Rudoll, T. L.; Needham, D.; Whorton, A.R.; Dewhirst, M. W. Increased Microvascular Permeability Contributes to Preferential Accumulation of Stealth Liposomes in Tumor Tissue. Cancer Res. 1993, 53, 3765-3770.
67. Lasic, D. D.; Papahadjopoulos, D. Liposomes Revisited. Science 1995, 267, 1275-1276
68. Rahman, A.; Treat, J.; Roh, J. K.; Potkul, L. A.; Alvord, W. G.; Forst, D.; Woolley, P. V. A Phase I Clinical Trial and Pharmacokinetic Evaluation of Liposome-Encapsulated Doxorubicin. J. Clin. Oncol. 1990, 8, 1093-1100.
69. Cowens, J. W.; Creaven, P. J.; Greco, W. R.; Brenner, D. E.; Tung, Y.; Ostro, M.; Pilkiewicz, F.; Ginsberg, R.; Petrelli, N. Initial Clinical (Phase I) Trial of TLC D-99 (Doxorubicin Encapsulated in Liposomes). Cancer Res. 1993, 53, 2796-2802.
70. Burke, T. G.; Mishra, A. K.; Wani, M. C.; Wall, M. E. Lipid Bilayer Partitioning and Stability of Camptothecin Drugs. Biochemistry 1993, 32, 5352-5364.
71. Burke, T. G.; Staubus, A. E.; Mishra, A. K. Liposomal Stabilization of Camptothecin's Lactone Ring. J. Am. Chem. Soc. 1992, 114, 8318-8319.
72. Daoud, S. S.; Fetouh, M. I.; Giovanella, B. C. Antitumor Effect of Liposome-Incorporated Camptothecin in Human Malignant Xenografts. Anticancer Drugs 1995, 6, 83-93.
73. Sugarman, S.M.; Zou, Y.; Wasan, K.; Poirot, K.; Kumi, R.; Reddy, S.; Perez-Soler, R. Lipid-Complexed Camptothecin: Formulation and Initial Biodistribution and Antitumor Activity Studies. Cancer Chemother. Pharmacol. 1996, 37, 531-538.
74. Tardi, P.; Choice, E.; Masin, D.; Redelmeier, T.; Bally, M.; Madden, T.D. Liposomal Encapsulation of Topotecan Enhances Anticancer Efficacy in Murine and Human Xenograft Models. Cancer Res. 2000, 60, 3389-3393.
75. Sadzuka, Y.; Hirota, S. Does The Amount of an Antitumor Agent Entrapped in Liposomes Influence Its Tissue Distribution and Cell Uptake? Cancer Lett. 1998, 131, 163-170.
76. Colbern, G.T.; Dykes, D.J.; Engbers, C.; Musterer, R.; Hiller, A.; Pegg, E.; Saville, R.; Weng, S.; Luzzio, M.; Uster, P.; Amantea, M.; Working, P.K. Encapsulation of the Topoisomerase I Inhibitor GL147211C in Pegylated (STEALTH) Liposomes: Pharmacokinetics and Antitumor Activity in HT29 Colon Tumor Xenografts. Clin. Cancer Res. 1998, 4, 3077-3082.
77. Emerson, D. L.; Bendele, R.; Brown, E.; Chiang, S.; Desjardins, J. P.; Dihel, L. C.; Gill, S. C.; Hamilton, M.; Leray, J. D.; Moon-Mcdermott, L.; Moynihan, K.; Richardson F. C.; Tomkinson, B.; Luzzio, M. J.; Baccanari, D. Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan. Clin. Cancer Res. 2000, 6, 2903-2912.
78. Desjardins, J. P.; Abbott, E. A.; Emerson, D. L.; Tomkinson, B. E.; Leray, J. D.; Brown, E.N.; Hamilton, M.; Dihel, L.; Ptaszynski, M.; Bendele, R. A.; Richardson, F.C. Biodistribution of NX211, Liposomal Lurtotecan, in Tumor-Bearing Mice. Anticancer Drugs 2001, 12, 235-245.
79. Kehrer, D. F.; Bos, A. M.; Verweij, J.; Groen, H. J.; Loos, W. J.; Sparreboom, A.; De Jonge, M.J.; Hamilton, M.; Cameron, T.; De Vries E.G. Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity. J. Clin. Oncol. 2002, 20, 1222-1231.
80. Chow, D. S.; Gong, L.; Wolfe, M. D.; Giovanella, B. C. Modified Lactone/Carboxylate Salt Equilibria in Vivo By Liposomal Delivery of 9-Nitro-Camptothecin. Ann. N. Y. Acad. Sci. 2000, 922, 164-174
81. Koshkina, N. V.; Kleinerman, E. S.; Waldrep, C.; Jia, S. F.; Worth, L. L.; Gilbert, B. E.; Knight, V. 9-Nitrocamptothecin Liposome Aerosol Treatment of Melanoma and Osteosarcoma Lung Metastases in Mice. Clin. Cancer Res. 2000, 6, 2876-2880.
82. Gilding, D.K.; Reed, A.M. Biodegradable Polymers for Use in Surgery, Polyglycolic/Poly(Lactic Acid) Homo- and Copolymers: 1. Polymer 1979, 20, 1459-1464.
83. Shenderova, A.; Burke, T. G.; Schwendeman, S.P. Stabilization of 10-Hydroxycamptothecin in Poly(Lactide-Co-Glycolide) Microsphere Delivery Vehicles. Pharm. Res. 1997, 14, 1406-1414.
84. Shenderova, A.; Burke, T. G.; Schwendeman, S. P. The Acidic Microclimate in Poly(Lactide-Co-Glycolide) Microspheres Stabilizes Camptothecins. Pharm. Res. 1999, 16, 241-248.
85. Yang, S. C.; Lu, L. F.; Cai, Y.; Zhu, J. B.; Liang, B. W.; Yang, C. Z. Body Distribution in Mice of Intravenously Injected Camptothecin Solid Lipid Nanoparticles and Targeting Effect on Brain. J. Control. Release 1999, 59, 299-307.
86. Yang, S.; Zhu, J.; Lu, Y.; Liang, B.; Yang, C. Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration. Pharm. Res. 1999, 16, 751-757
87. Conover, C.D.; Greenwald, R.B.; Pendri, A.; Shum, K.L. Camptothecin Delivery Systems: The Utility of Amino Acid Spacers fort he Conjugation of Camptothecin with Polyethylene Glycol to Create Prodrugs. Anticancer Drug 1999, 14, 499-506
88. Seymour, L.W. Passive Tumor Targeting of Soluble Macromolecules and Drug Conjugates. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9, 135-187
89. Duncan, R. Drug-Polymer Conjugates: Potential for Improved Chemotherapy. Anticancer Drugs 1992, 3, 175-210
90. Kratz, F.; Beyer, U.; Schutte, M.T. Drug-Polymer Conjugates Containing Acid-Cleavable Bonds. Crit. Rev. Ther. Drug Carrier Syst. 1999, 16, 245-288
91. Singer, J.W.; De Vries, P.; Bhatt, R.; Tulinsky, J.; Klein, P.; Li, C.; Milas, L.; Lewis, R.A.; Wallace, S. Conjugation of Camptothecins to Poly-(L-Glutamic Acid). Ann. N. Y. Acad. Sci. 2000, 922, 136-150
92. Hersey, J.A.; Cook, P.C. Homogeneity of Pharmaceutical Dispersed Systems. J. Pharm. Pharmacol. 1974, 26, 126-133
93. Smith, S.J.; Bernstein, J.A. Therapeuti Uses of Lung Aearosols. Lung Biol. Health Dis. 1996, 94, 233-269
94. Imbeau, S.A. Aerosol Beclomethasone Treatment of Chronic Severe Asthma. A One-Year Experience. J. Am. Med. Assoc. 1978, 240, 1260-1262
95. Shim, C. Adrenergic Agonists and Bronchodilator Aerosol Therapy in Asthma. Clin. Chest Med. 1984, 5, 659-668
96. Conte, J. E. Jr.; Chernoff, D.; Feigal, D. W. Jr.; Joseph, P.; Mcdonald, C.; Golden, J.A. Intravenous or Inhaled Pentamidine for Treating Pneumocystis Carinii Pneumonia in AIDS. A Randomized Trial. Ann. Intern. Med. 1990, 113, 203-209
97. Aylward, R. B.; Burdge, D. R. Ribavirin Therapy of Adult Respiratory Syncytial Virus Pneumonitis. Arch. Intern. Med. 1991, 151, 2303-2304
98. Ramsey, B. W.; Dorkinm H. L.; Eisenberg, J. D.; Gibson, R. L.; Harwood, I. R.; Kravitz, R. M.; Schidlow, D. V.; Wilmott, R. W.; Astley, S. J.; Mcburnie, M. A.; Wentz, K.; Smith, A. L. Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis. N. Engl. J. Med. 1993, 328, 1740-1746
99. Shevchenko, I.T.; Resnik, G.E. Inhalation of Chemical Substances and Oxygen in Radiotherapy of Bronchial Cancer. Neoplasma 1968, 15, 419-426
100. Tatsumura, T.; Koyama, S.; Tsujimoto, M.; Kitagawa, M.; Kagamimori, S. Further Study of Nebulisation Chemotherapy, A New Chemotherapeutic Method in The Treatment of Lung Carcinomas: Fundamental and Clinical. Br. J. Cancer 1993, 68, 1146-1149.
101. Halme, M.; Maasilta, P.; Repo, H.; Ristola, M.; Taskinen, E.; Mattson, K.; Cantell, K. Inhaled Recombinant Interferon Gamma in Patients with Lung Cancer: Pharmacokinetics and Effects on Chemiluminescence Responses of Alveolar Macrophages and Peripheral Blood Neutrophils and Monocytes. Int. J. Radiat. Oncol. Biol. Phys. 1995, 31, 93-101.
102. Anderson, P. M.; Markovic, S. N.; Sloan, J. A.; Clawson, M. L.; Wylam, M.; Arndt, C. A.; Smithson, W. A.; Burch, P.; Gornet, M.; Rahman, E. Aerosol Granulocyte Macrophage-Colony Stimulating Factor: a Low Toxicity, Lung-Specific Biological Therapy in Patients with Lung Metastases. Clin. Cancer Res. 1999, 5, 2316-2323.
103. Koshkina, N. V.; Gilbert, B. E.; Waldrep, J. C.; Seryshev, A.; Knight, V. Distribution of Camptothecin After Delivery as a Liposome Aerosol or Following Intramuscular Injection in Mice. Cancer Chemother. Pharmacol. 1999, 44, 187-192.
104. Patton, J. C. Mechanism of Macromolecule Absorbtion by the Lungs. Adv. Drug Delivery Rev. 1996, 19, 3-36.
105. Giovanella, B.C.; Natelson, E.; Harris, N.; Vardeman, D.; Stehlin, J.S. Protocols for The Treatment of Human Tumor Xenografts with Camptothecins. Ann N. Y. Acad. Sci. 1996, 803, 181-187.
106. Nakashio A, Fujita N, Tsuruo T. Topotecan Inhibits VEGF- and Bfgf-Induced Vascular Endothelial Cell Migration Via Downregulation of the PI3K-Akt Signaling Pathway. Int. J. Cancer 2002, 98, 36-41.
107. Giovanella, B. C.; Hinz, H. R.; Kozielski, A. J.; Stehlin, J. S. Jr.; Silber, R.; Potmesil, M. Complete Growth Inhibition of Human Cancer Xenografts in Nude Mice by Treatment with 20-(S)-Camptothecin. Cancer Res. 1991, 51, 3052-3055
108. Gilbert, B. E.; Seryshev, A.; Knight, V.; Brayton, C. 9-Nitrocamptothecin Liposome Aerosol: Lack of Subacute Toxicity in Dogs. Inhalation Therapy 2002, 14, 185-197
109. Verschraegen, C. F.; Gilbert, B. E.; Huaringa, A. J.; Newman, R.; Harris, N.; Leyva, F.J.; Keus, L.; Campbell, K.; Nelson-Taylor, T.; Knight V. Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs. Ann. N. Y. Acad. Sci. 2000, 922, 352-354
110. Gautam, A.; Waldrep, J. C.; Densmore, C. L.; Koshkina, N. V.; Melton, S.; Roberts, L.; Gilbert, B.; Knight, V. Growth Inhibition of Established B16-F10 Lung Metastases by Sequential Aerosol Delivery of p53 Gene and 9-Nitrocamptothecin. Gene Therapy 2002, 9, 353-357
111. Koshkina, N. V.; Knight, V.; Gilbert, B. E.; Golunski, E.; Roberts, L.; Waldrep, J. C. Improved Respiratory Delivery of the Anticancer Drugs, Camptothecin and Paclitaxel, with 5% CO2-Enriched Air: Pharmacokinetic Studies, Cancer Chemother. Pharmacol. 2001, 47, 451-456.
112. Gautam, A.; Densmore, C. L.; Xu, B.; Waldrep, J. C. Enhanced Gene Expression in Mouse Lung After PEI-DNA Aerosol Delivery. Mol. Ther. 2000, 2, 63-70.